Introduction
============

Recently, it has been suggested that infection with *Helicobacter pylori* may have a pathogenic role in diabetes mellitus.[@b1-jcm-4-2013-041]--[@b3-jcm-4-2013-041] However, there is no definite evidence regarding the role of *H. pylori* infection that may cause insulin resistance. In the present study, we aimed to elucidate whether *H. pylori* deteriorates glycemic control in subjects with diabetes mellitus. To do so, we retrospectively investigated the effect of eradication therapy on *H. pylori* and how it might affect glycemic control in Japanese subjects with type 2 diabetes.

Subjects and Methods
====================

The study included a total of 72 subjects with type 2 diabetes who received eradication therapy for *H. pylori* during 6 years from 2006 to 2011. Subjects gave their oral consent for use of their clinical data in this study. They included 55 male and 17 female subjects, aged 63.7 \[standard error (SE) 1.1\] years, and we checked A1C levels regularly in our division. At first, the subjects were pathologically diagnosed with *H. pylori* infection by upper gastrointestinal endoscopy. The eradication therapy for *H. pylori* was performed using oral administration of amoxicillin 1500 mg/day, clarithromycin 800 mg/day with lansoprazole 60 mg/day (n = 65) or omeprazole 40 mg/day (n = 2), or rabeprazole 40 mg/ day (n = 5) for 7 days. The eradication was evaluated by urea breath test and the subjects who failed to eradicate *H. pylori* were excluded. The blood glycosylated hemoglobin (A1C) levels were evaluated 3 months before (−3 m) the eradication therapy, as well as 3 months (3 m) and 6 months (6 m) after. The subjects had been treated with sulfonylureas (58.3%), alpha-glucosidase inhibitors (19.4%), biguanides (18.1%), dipeptidyl pep-tidase-4 inhibitors (9.7%), glinides (4.2%) and thiazo-lidinedione (1.4%), or with insulin (11.1.%); 27.8% of subjects did not receive any medications. An unpaired *t*-test was used to compare A1C levels before and after the eradication. Statistical analysis was performed with SPSS-II (SPSS Inc, Chicago, IL, USA) for WINDOWS^®^ (Microsoft Corporation, Redmond, WA).

Results
=======

The A1C levels before and after the eradication therapy for *H. pylori* did not show any significant changes in subjects with type 2 diabetes {6.9 \[0.1\]% (−3 m) to 7.0 \[0.1\]% (3 m); *P* = 0.3, 7.0 \[0.1\] (6 m); *P* = 0.3} ([Fig. 1](#f1-jcm-4-2013-041){ref-type="fig"}). Scatter plotting also revealed that the A1C levels of each subject had not been changed during the study period ([Fig. 2](#f2-jcm-4-2013-041){ref-type="fig"}).

Discussion
==========

Infection with *H. pylori* has been recently suggested to be associated with an increased rate of diabetes mellitus.[@b2-jcm-4-2013-041] A previous report found that *H. pylori* infection might be associated with insulin-dependent diabetes mellitus.[@b1-jcm-4-2013-041] A case report from Japan has also suggested that the eradication of *H. pylori* may result in the amelioration of insulin resistance in a patient with type B insulin resistance, (ie, insulin receptor autoantibodies).[@b3-jcm-4-2013-041] However, another case report from Japan indicated that the eradication of *H. pylori* might trigger the onset of type 1 diabetes.[@b4-jcm-4-2013-041]

Although our study is limited by the fact that it is a retrospective analysis from one center with a small number of subjects, the present findings suggest that eradication therapy for *H. pylori* does not, at least profoundly, affect glycemic control in Japanese subjects with type 2 diabetes. Further investigation is needed to determine whether autoantibodies against insulin or islet cells possibly triggered by *H. pylori* infection might be an irreversible process.

Conclusion
==========

The eradication therapy for *H. pylori* does not seem to affect glycemic control in Japanese subjects with type 2 diabetes.
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![Change in A1C levels before 3 m, as well as after 3 m and 6 m of *H. pylori* eradication.\
**Note:** There was no significant change in A1C levels.](jcm-4-2013-041f1){#f1-jcm-4-2013-041}
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